95% CI, 0.08 to 4.21) [79]
2.4 Assessments Safety assessments included AEs, hypoglycaemic episodes, laboratory safety parameters, physical examination, vital signs and electrocardiogram
Approval or Denial: If Approved: Youll receive: Explanation of prescribed dose Injection training materials or video Information about your pharmacy Timeline for delivery Follow-up schedule Contact information for questions If Not Approved: Your provider should explain: Specific reason for denial Alternative options to consider Whether you might qualify in the future Other weight loss approaches Common Reasons for Denial: BMI below threshold without qualifying conditions Contraindications (thyroid cancer history, pregnancy, MEN 2) Dangerous medication interactions Medical conditions making semaglutide unsafe Unrealistic expectations or poor understanding of treatment Most providers want to help but must prioritize safety
Other common side effects include constipation, diarrhea, and acid reflux
RD is a co-inventor on intellectual property owned by Indiana University and licensed to Novo Nordisk
Timeline expectations: Weeks 1-4: Peak gas production as your body adjusts to medication Months 2-3: Gradual improvement for most users as digestive system adapts Month 6+: Significant reduction in symptoms, though some sensitivity may remain The silver lining: Most people find that gas issues dramatically improve after the initial adjustment period, and the weight loss benefits often outweigh the temporary digestive drama
